Skip to main content

datastreet.in

Subscribe
Facebook-f Instagram Twitter Youtube

Sun Pharma’s Unloxcyt posts 50% response rate in skin cancer study

Updated data from the CK-301-101 trial showed durable responses and manageable safety profile in patients with locally advanced cutaneous squamous cell carcinoma

Source :- Companies Read More

Share it :

Leave a Reply

Your email address will not be published. Required fields are marked *

Get free tips and resources right in your inbox, along with 10,000+ others

Categories

Latest Post

logo_neonews.png
Subscribe